Monopar Therapeutics (NASDAQ:MNPR) Sets New 52-Week High – Should You Buy?

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) reached a new 52-week high during trading on Monday . The company traded as high as $115.00 and last traded at $111.2940, with a volume of 10976 shares trading hands. The stock had previously closed at $111.12.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MNPR. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday. BTIG Research raised their price objective on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Chardan Capital reiterated a “buy” rating and issued a $100.00 target price on shares of Monopar Therapeutics in a report on Monday, March 30th. Finally, HC Wainwright restated a “buy” rating and set a $105.00 price target on shares of Monopar Therapeutics in a report on Monday, June 29th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $108.75.

Monopar Therapeutics Stock Down 2.4%

The firm has a market cap of $726.51 million, a price-to-earnings ratio of -56.96 and a beta of 1.46. The company’s 50-day moving average price is $75.72 and its 200-day moving average price is $65.12.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.41. On average, sell-side analysts predict that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

Institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics in the third quarter valued at $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at $65,000. JPMorgan Chase & Co. boosted its stake in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $80,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.